Endpoints
ADVERSE EVENT, SECONDARY, ADVERSE EVENT
The final prespecified analyses of the primary endpoint of investigator-assessed PFS and the secondary endpoint of OS, as well as the extended follow-up (median, 56.3 months) analysis of MONALEESA-3, have been reported previously [Survival follow-up continued for patients who discontinued study treatment. Adverse events (AEs) were monitored and graded according to the Common Terminology Criteria for Adverse Events (version 4.03) [